Mutant Mosquitoes Deployed to Stop Zika, Dengue

A Brazilian town will ramp up the release of insects engineered to shrink mosquito populations.

Written byKerry Grens
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, EMIL AUGUST GOELDIOxitec, a company that breeds genetically modified (GM) mosquitoes whose offspring die young, is launching a facility in Piracicaba, Brazil, to combat viral infections transmitted by Aedes aegypti mosquitoes. Already, Oxitec had been releasing its mosquitoes in a small region of Piracicaba; the program will now expand to the city center.

“This will bring to the city a new Oxitec factory to meet demand for years to come and help protect the public’s health with this clean and innovative technology,” Mayor Gabriel Ferrato said in a press release.

Oxitec’s program in Piracicaba began in April 2015, and, according to the press release, wild mosquito larvae numbers dropped 82 percent by the end of the year. The mosquitoes are genetically modified so that when mated with wild-type mosquitoes produce larvae that don’t make it to adulthood.

Thomas Scott, who studies vector-borne diseases at the University of California, Davis, said the results from field trials are encouraging. “It will be helpful if future trials can demonstrate disease reduction, determine that the strategy can be scaled-up to modern mega-cities ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • kerry grens

    Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at WHYY in Philadelphia, and the health and science reporter at New Hampshire Public Radio. Kerry got her start in journalism as a AAAS Mass Media fellow at KUNC in Colorado. She has a master’s in biological sciences from Stanford University and a biology degree from Loyola University Chicago.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies